Turkey: Produce Selected Drugs Locally Or Lose Reimbursement
Executive Summary
Turkey’s public payer body has said it will halt reimbursement of 54 products from 2018 unless manufacturers, including several multinationals, agree to start local production within a year.
You may also be interested in...
New Turkish Biosimilar Insulin Glargine Poses Challenge For Sanofi’s Lantus
Koçak Farma’s launch of a biosimilar version of Lantus could encourage Sanofi to invest in local production in Turkey, especially if the originator is at risk of being left off the reimbursement list.
New Turkish Biosimilar Insulin Glargine Poses Challenge For Sanofi’s Lantus
Koçak Farma’s launch of a biosimilar version of Lantus could encourage Sanofi to invest in local production in Turkey, especially if the originator is at risk of being left off the reimbursement list.
Medtech Procurement A Victim Of Turkey’s Ongoing Economic Troubles
The devaluation of the Turkish Lira since May is making imports of medical devices more expensive and putting hospital procurement under renewed pressure. The local medtech industry associations TUMDEF and ARTED describe the problems ̶ and the solutions ̶ to Medtech Insight.